It is possible that enkephalins are involved in the pain-modulating mechanism in the spinal cord. Enkephalins, however, are short-lived, being rapidly degraded by various endogenous enzymes. Many substances that inhibit enkephalin-degradation have been investigated and it has been reported that some inhibitors (e.g. kelatorphan and RB101) alone showed anti-nociceptive activity. We found an endogenous factor that modulated enkephalin-degrading activity and purified it from bovine spinal cord based on its inhibitory activity toward enkephalin-degrading enzymes. Structural analysis revealed the factor to be Leu-Val-Val-Tyr-Pro-Trp-Thr and it was named spinorphin. It has been found that spinorphin inhibited the activity toward various enkephalin-degrading enzymes from monkey brain, especially dipeptidyl peptidase III (DPPIII, Ki=5.1 x 10(-7) M). Recently we reported that this inhibitor significantly inhibited bradykinin (BK)-induced nociceptive flexor responses. Importantly, the mode of inhibition to BK-responses by spinorphin was different from the case with morphine. The morphine-induced blockade of BK-response was attenuated by pertussis toxin treatment, whereas that of spinorphin was not. We also have reported roles for spinorphin in inflammation. Spinorphin significantly inhibited the functions of polymorphonuclear neutrophils (PMNs) by suppressing the binding of fMLF to its receptor on PMNs. Further, this inhibitor suppressed the carrageenan-induced accumulation of PMN in mouse air pouches after intravenous administration. These results indicate that spinorphin may be an endogenous anti-inflammatory regulator. The possible role of spinorphin and its analog as regulators in pain and inflammation will be discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389203023380404 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modulation of endogenous opioid signaling by inhibitors of puromycin-sensitive aminopeptidase.
Eur J Med Chem
September 2024
Center for Drug Design, College of Pharmacy, University of Minnesota, MN, USA. Electronic address:
Article Synopsis
- The endogenous opioid system helps regulate pain through the release of neuropeptides, but opioid peptides like enkephalins are quickly broken down by enzymes, limiting their effectiveness.
- A novel approach to manage pain involves developing inhibitors that prevent the breakdown of enkephalins, with previous studies identifying a promising compound that needs refinement to avoid toxic side effects.
- The new compound improved pain relief and showed strong interaction with opioid receptors, while further research indicated it has good stability in the body and supports the continued development of these inhibitors for better pain management.
Modulation of endogenous opioid signaling by inhibitors of puromycin sensitive aminopeptidase.
bioRxiv
April 2024
Center for Drug Design, College of Pharmacy, University of Minnesota, MN, USA.
Article Synopsis
- The endogenous opioid system manages pain through neuropeptides like enkephalins, but their effectiveness is limited because they are quickly broken down by enzymes.
- An innovative solution proposed is to create drugs that inhibit these enzymes, specifically puromycin sensitive aminopeptidase (PSA), to increase the stability and concentration of enkephalins for longer-lasting pain relief.
- New derivatives of existing compounds showed promise by maintaining PSA inhibition without causing toxicity, leading to significant pain reduction in tests, and confirming the role of opioid receptors in the analgesic effects observed.
Structure of puromycin-sensitive aminopeptidase and polyglutamine binding.
PLoS One
July 2023
Department of Molecular and Cellular Biochemistry and Center for Structural Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Puromycin-sensitive aminopeptidase (E.C. 3.
View Article and Find Full Text PDFRapid imaging of lung cancer using a red fluorescent probe to detect dipeptidyl peptidase 4 and puromycin-sensitive aminopeptidase activities.
Sci Rep
June 2022
Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Rapid identification of lung-cancer micro-lesions is becoming increasingly important to improve the outcome of surgery by accurately defining the tumor/normal tissue margins and detecting tiny tumors, especially for patients with low lung function and early-stage cancer. The purpose of this study is to select and validate the best red fluorescent probe for rapid diagnosis of lung cancer by screening a library of 400 red fluorescent probes based on 2-methyl silicon rhodamine (2MeSiR) as the fluorescent scaffold, as well as to identify the target enzymes that activate the selected probe, and to confirm their expression in cancer cells. The selected probe, glutamine-alanine-2-methyl silicon rhodamine (QA-2MeSiR), showed 96.
View Article and Find Full Text PDFPSA controls hepatic lipid metabolism by regulating the NRF2 signaling pathway.
J Mol Cell Biol
October 2021
Department of Endocrinology, Translational Research of Diabetes Key Laboratory of Chongqing Education Commission of China, The Second Affiliated Hospital of Army Medical University, Chongqing, China.
The activity of proteinase is reported to correlate with the development and progression of nonalcoholic fatty liver disease (NAFLD). Puromycin-sensitive aminopeptidase (PSA/NPEPPS) is an integral nontransmembrane enzyme that functions to catalyze the cleavage of amino acids near the N-terminus of polypeptides. A previous study suggested that this enzyme acts as a regulator of neuropeptide activity; however, the metabolic function of this enzyme in the liver has not been explored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!